Synopsis of the 2020 American Diabetes Association’s Standards of Medical Care in Diabetes Clinical Guideline (Annals of Internal Medicine)
Diabetes News
Category: Treatment
Efficacy of GAD-alum immunotherapy associated with HLA-DR3-DQ2 in recently diagnosed type 1 diabetes
GAD65-specific immunotherapy has a significant effect on C-peptide retention in individuals with recent-onset type 1 diabetes who have the DR3-DQ2 haplotype (Diabetologia)
Compatibility and Safety of Ultra Rapid Lispro with Continuous Subcutaneous Insulin Infusion in Patients with Type 1 Diabetes: PRONTO-Pump Study
URLi was compatible with insulin pump use with a safety profile similar to lispro (Diabetes Technology and Therapeutics)
Bile Acids: Key Regulators and Novel Treatment Targets for Type 2 Diabetes
we provide an overview of the mechanisms underlying the role of bile acids in glucose and lipid metabolism, as well as the occurrence and development of T2DM. Bile acid-targeted therapy may represent a valid approach for T2DM treatment (Journal of Diabetes Research)
Defining the Future of Endocrine Services in the UK
The Society for Endocrinology has set up a work stream called “Defining the Future of Endocrinology working group”, in the post Covid era (ABCD)
Treatment Options for MODY Patients: A Systematic Review of Literature
Our aim is to provide the reader with an easy-to-read update that can be used to drive the clinician’s therapeutical approach to these patients after the molecular diagnosis (Diabetes Therapy)
Rationale for Timely Insulin Therapy in Type 2 Diabetes Within the Framework of Individualised Treatment: 2020 Update
Timely insulin initiation may prevent diabetes progression, reduce diabetes-related complications and has less serious adverse effects (Diabetes Therapy)
Patient‐reported outcomes after 10‐year follow‐up of intensive, multifactorial treatment in individuals with screen‐detected type 2 diabetes: the ADDITION‐Europe trial
Intensive, multifactorial treatment of individuals with screen‐detected type 2 diabetes did not affect self‐reported health status, diabetes‐specific quality of life, or diabetes treatment satisfaction at 10‐year follow‐up compared to routine care (Diabetic Medicine)
The Australian response to the COVID-19 pandemic and diabetes – lessons learned
Once the COVID-19 pandemic is over, review of all the changes will be important, determining which should be permanently implemented. The learnings from COVID-19 should help prepare Australia for future pandemics or other major health crises (Diabetes Research and Clinical Practice)
Early sepsis markers in patients admitted to intensive care unit with moderate-to-severe diabetic ketoacidosis
At admission, combining procalcitonin and presence of fever may be of value to distinguish ketoacidosis patients with and without proven bacterial infection, admitted in intensive care unit (Annals of Intensive Care)
Outcomes in Patients With Hyperglycemia Affected by Covid-19: Can We Do More on Glycemic Control?
Insulin infusion may be an effective method for achieving glycemic targets and improving outcomes in patients with Covid-19 (Diabetes Care)
Hyperglycemia in Medically Critically Ill Patients: Risk Factors and Clinical Outcomes
In our high acuity medically critically ill patient population, achieving time-weighted average daily blood glucose levels <180mg/dl reliably while in the ICU significantly decreased the odds of subsequent hospital mortality. Suboptimal glycemic control during the ICU stay, on the other hand, significantly increased the odds of a longer-than-predicted ICU and hospital stay (American Journal of Medicine)
The Effects of Intensive Glycemic Control on Clinical Outcomes Among Patients With Type 2 Diabetes With Different Levels of Cardiovascular Risk and Hemoglobin A1c in the ADVANCE Trial
The major benefits for patients with T2D in ADVANCE did not substantially differ across levels of baseline ASCVD risk and HbA1c (Diabetes Care)
Initial Glycemic Control and Care Among Younger Adults Diagnosed With Type 2 Diabetes
Adults with onset of type 2 diabetes at a younger age were less likely to achieve glycemic control at 1 year following diagnosis, suggesting the need for tailored care approaches to improve outcomes for this high-risk patient population (Diabetes Care)
Hypoglycemia during Short-Term Intensive Insulin Therapy and Its Association with Long-Term Glycemic Remission in Patients with Newly Diagnosed Type 2 Diabetes
Mild hypoglycemic episodes during the continuing insulin dose reduction period indicate a long-term drug-free euglycemic remission in patients with newly diagnosed type 2 diabetes. However, the insulin dosage should be reduced even more quickly in the future treatment to decrease the potential harms (Journal of Diabetes Research)
IWGDF Guidelines on the prevention and management of diabetic foot disease
The International working Group on the Diabetic Foot (IWGDF) has been producing evidence-based guidelines on the prevention and management of diabetic foot disease since 1999. In 2019, all IWGDF Guidelines have been updated, based on systematic reviews of the literature and formulation of recommendations by multidisciplinary experts from all over the world (International Working Group on the Diabetic Foot (IWGDF) )
A Novel Dual-Hormone Insulin-and-Pramlintide Artificial Pancreas for Type 1 Diabetes: A Randomized Controlled Crossover Trial
A novel rapid insulin-and-pramlintide artificial pancreas improves glucose control compared with a rapid insulin-alone artificial pancreas (Diabetes Care)
Standards of Medical Care in Diabetes—2020 Abridged for Primary Care Providers
The American Diabetes Association’s (ADA’s) Standards of Medical Care in Diabetes is updated and published annually in a supplement to the January issue of Diabetes Care
A qualitative study of clinician attitudes towards closed‐loop systems in mainstream diabetes care in England
Clinicians recognize the value of closed‐loop systems in terms of health benefits, but also identify a range of concerns for both users and healthcare staff, which could impact negatively on user access (Diabetic Medicine)
Effectiveness and Safety of Insulin Glargine 300 U/mL in Insulin‐Naïve Patients with Type 2 Diabetes after Failure of Oral Therapy in a Real World Setting
Starting a BOT regimen with Gla‐300 allowed about 60% of 721 German and Swiss patients with inadequately controlled type 2 diabetes to achieve glycaemic control within 12 months in daily clinical practice. Glycaemic control was achieved without weight gain or increased risk of nocturnal or severe hypoglycaemia (Diabetes, Obesity and Metabolism)
- 1
- 2
- 3
- …
- 22
- Next Page »
Glycosmedia is also available as an App: